Suppr超能文献

调节和成像巨噬细胞重编程用于癌症免疫治疗

Modulating and Imaging Macrophage Reprogramming for Cancer Immunotherapy.

作者信息

Wang Jialu, Lu Yafang, Zhang Ren, Cai Zhenzhen, Fan Zhan, Xu Yilun, Liu Zheng, Zhang Zhihong

机构信息

Britton Chance Center and MOE Key Laboratory for Biomedical Photonics, Wuhan National Laboratory for Optoelectronics, Huazhong University of Science and Technology, Wuhan, 430074 Hubei China.

Key Laboratory of Biomedical Engineering of Hainan Province, School of Biomedical Engineering, Hainan University, Haikou, 570228 Hainan China.

出版信息

Phenomics. 2024 Jun 22;4(4):401-414. doi: 10.1007/s43657-023-00154-6. eCollection 2024 Aug.

Abstract

Cancer immunotherapy has made great progress in effectively attacking or eliminating cancer. However, the challenges posed by the low reactivity of some solid tumors still remain. Macrophages, as a key component of the tumor microenvironment (TME), play an important role in determining the progression of solid tumors due to their plasticity and heterogeneity. Targeting and reprogramming macrophages in TME to desired phenotypes offers an innovative and promising approach for cancer immunotherapy. Meanwhile, the rapid development of in vivo molecular imaging techniques provides us with powerful tools to study macrophages. In this review, we summarize the current progress in macrophage reprogramming from conceptual roadmaps to therapeutic approaches, including monoclonal antibody drugs, small molecule drugs, gene therapy, and chimeric antigen receptor-engineered macrophages (CAR-M). More importantly, we highlight the significance of molecular imaging in observing and understanding the process of macrophage reprogramming during cancer immunotherapy. Finally, we introduce the therapeutic applications of imaging and reprogramming macrophages in three solid tumors. In the future, the integration of molecular imaging into the development of novel macrophage reprogramming strategies holds great promise for precise clinical cancer immunotherapy.

摘要

癌症免疫疗法在有效攻击或消除癌症方面取得了巨大进展。然而,一些实体瘤反应性低所带来的挑战仍然存在。巨噬细胞作为肿瘤微环境(TME)的关键组成部分,由于其可塑性和异质性,在决定实体瘤的进展中起着重要作用。将TME中的巨噬细胞靶向并重编程为所需表型为癌症免疫疗法提供了一种创新且有前景的方法。同时,体内分子成像技术的快速发展为我们研究巨噬细胞提供了强大工具。在本综述中,我们总结了巨噬细胞重编程从概念路线图到治疗方法的当前进展,包括单克隆抗体药物、小分子药物、基因治疗和嵌合抗原受体工程化巨噬细胞(CAR-M)。更重要的是,我们强调了分子成像在观察和理解癌症免疫疗法期间巨噬细胞重编程过程中的重要性。最后,我们介绍了成像和重编程巨噬细胞在三种实体瘤中的治疗应用。未来,将分子成像整合到新型巨噬细胞重编程策略的开发中,对精确的临床癌症免疫疗法具有巨大的前景。

相似文献

1
Modulating and Imaging Macrophage Reprogramming for Cancer Immunotherapy.
Phenomics. 2024 Jun 22;4(4):401-414. doi: 10.1007/s43657-023-00154-6. eCollection 2024 Aug.
2
From spheroids to organoids: next-generation models for CAR-T cell therapy research in solid tumors.
Front Immunol. 2025 Jul 11;16:1626369. doi: 10.3389/fimmu.2025.1626369. eCollection 2025.
5
Systemic treatments for metastatic cutaneous melanoma.
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
7
Tumor therapy by targeting extracellular hydroxyapatite using novel drugs: A paradigm shift.
Cancer Med. 2024 Feb;13(3):e6812. doi: 10.1002/cam4.6812. Epub 2024 Jan 18.
9
Recombinant cytokine bioconjugates with degradable nanogel substrates for macrophage immunotherapy.
Acta Biomater. 2025 Jul 1;201:604-617. doi: 10.1016/j.actbio.2025.05.066. Epub 2025 May 29.

引用本文的文献

2
Unleashing the power of CAR-M therapy in solid tumors: a comprehensive review.
Front Immunol. 2025 Jun 12;16:1615760. doi: 10.3389/fimmu.2025.1615760. eCollection 2025.
3
Advances in Multimodal Imaging Techniques for Evaluating and Predicting the Efficacy of Immunotherapy for NSCLC.
Cancer Manag Res. 2025 Jun 7;17:1073-1086. doi: 10.2147/CMAR.S522136. eCollection 2025.

本文引用的文献

1
CD8 T cells maintain killing of MHC-I-negative tumor cells through the NKG2D-NKG2DL axis.
Nat Cancer. 2023 Sep;4(9):1258-1272. doi: 10.1038/s43018-023-00600-4. Epub 2023 Aug 3.
2
Roles of macrophages in tumor development: a spatiotemporal perspective.
Cell Mol Immunol. 2023 Sep;20(9):983-992. doi: 10.1038/s41423-023-01061-6. Epub 2023 Jul 10.
3
MCT4-dependent lactate secretion suppresses antitumor immunity in LKB1-deficient lung adenocarcinoma.
Cancer Cell. 2023 Jul 10;41(7):1363-1380.e7. doi: 10.1016/j.ccell.2023.05.015. Epub 2023 Jun 15.
4
Capturing hyperspectral images.
Nat Methods. 2023 Jun;20(6):783. doi: 10.1038/s41592-023-01921-z.
5
Macrophages in immunoregulation and therapeutics.
Signal Transduct Target Ther. 2023 May 22;8(1):207. doi: 10.1038/s41392-023-01452-1.
6
Design of a novel chimeric peptide via dual blockade of CD47/SIRPα and PD-1/PD-L1 for cancer immunotherapy.
Sci China Life Sci. 2023 Oct;66(10):2310-2328. doi: 10.1007/s11427-022-2285-6. Epub 2023 Apr 21.
7
Tissue-specific macrophages: how they develop and choreograph tissue biology.
Nat Rev Immunol. 2023 Sep;23(9):563-579. doi: 10.1038/s41577-023-00848-y. Epub 2023 Mar 15.
8
CD40 signal rewires fatty acid and glutamine metabolism for stimulating macrophage anti-tumorigenic functions.
Nat Immunol. 2023 Mar;24(3):452-462. doi: 10.1038/s41590-023-01430-3. Epub 2023 Feb 23.
9
A timeline of tumour-associated macrophage biology.
Nat Rev Cancer. 2023 Apr;23(4):238-257. doi: 10.1038/s41568-022-00547-1. Epub 2023 Feb 15.
10
YTHDF2 orchestrates tumor-associated macrophage reprogramming and controls antitumor immunity through CD8 T cells.
Nat Immunol. 2023 Feb;24(2):255-266. doi: 10.1038/s41590-022-01398-6. Epub 2023 Jan 19.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验